Log in

NASDAQ:ORTXOrchard Therapeutics Stock Price, Forecast & News

$9.34
-0.18 (-1.89 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$9.21
Now: $9.34
$9.89
50-Day Range
$8.85
MA: $10.29
$11.99
52-Week Range
$5.17
Now: $9.34
$17.48
Volume299,901 shs
Average Volume322,778 shs
Market Capitalization$908.41 million
P/E RatioN/A
Dividend YieldN/A
Beta1.12
Orchard Therapeutics plc, integrated biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration. Its commercial stage products include Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-201 for mucopolysaccharidosis type IIIA and OTL-202 for mucopolysaccharidosis type IIIB. The company was formerly known as Orchard Rx Ltd. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.49 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ORTX
CUSIPN/A
CIKN/A
Phone011-44-0-203-3846700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.51 million
Book Value$3.11 per share

Profitability

Net Income$-163,420,000.00

Miscellaneous

Employees180
Market Cap$908.41 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive ORTX News and Ratings via Email

Sign-up to receive the latest news and ratings for ORTX and its competitors with MarketBeat's FREE daily newsletter.

Orchard Therapeutics (NASDAQ:ORTX) Frequently Asked Questions

How has Orchard Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Orchard Therapeutics' stock was trading at $9.08 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ORTX stock has increased by 2.9% and is now trading at $9.34. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Orchard Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Orchard Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Orchard Therapeutics.

When is Orchard Therapeutics' next earnings date?

Orchard Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Orchard Therapeutics.

How were Orchard Therapeutics' earnings last quarter?

Orchard Therapeutics PLC - (NASDAQ:ORTX) announced its earnings results on Thursday, May, 7th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.50) by $0.01. View Orchard Therapeutics' earnings history.

What price target have analysts set for ORTX?

5 equities research analysts have issued 12-month price targets for Orchard Therapeutics' shares. Their forecasts range from $17.00 to $31.00. On average, they expect Orchard Therapeutics' share price to reach $24.60 in the next year. This suggests a possible upside of 163.4% from the stock's current price. View analysts' price targets for Orchard Therapeutics.

Has Orchard Therapeutics been receiving favorable news coverage?

News coverage about ORTX stock has been trending extremely negative this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Orchard Therapeutics earned a media sentiment score of -5.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days. View the latest news aboutOrchard Therapeutics.

Who are some of Orchard Therapeutics' key competitors?

What other stocks do shareholders of Orchard Therapeutics own?

Who are Orchard Therapeutics' key executives?

Orchard Therapeutics' management team includes the following people:
  • Mr. Mark A. Rothera, CEO, Pres & Director (Age 56)
  • Dr. Anne Dupraz-Poiseau, Chief Regulatory Officer
  • Mr. Frank E. Thomas, CFO & Chief Bus. Officer (Age 49)
  • Ms. Ran Zheng, Chief Technical Officer
  • Prof. Bobby Gaspar Ph.D., M.D., Chief Scientific Officer, Director & Member of Scientific Advisory Board (Age 54)

When did Orchard Therapeutics IPO?

(ORTX) raised $200 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 13,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Orchard Therapeutics' stock symbol?

Orchard Therapeutics trades on the NASDAQ under the ticker symbol "ORTX."

Who are Orchard Therapeutics' major shareholders?

Orchard Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include RA Capital Management L.P. (10.66%), Wellington Management Group LLP (2.44%), Vivo Capital LLC (1.67%), ArrowMark Colorado Holdings LLC (1.53%), Driehaus Capital Management LLC (1.48%) and Janus Henderson Group PLC (1.01%). View institutional ownership trends for Orchard Therapeutics.

Which major investors are selling Orchard Therapeutics stock?

ORTX stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Wellington Management Group LLP, Cormorant Asset Management LP, Canada Pension Plan Investment Board, Ghost Tree Capital LLC, Nuveen Asset Management LLC, Driehaus Capital Management LLC, and Alps Advisors Inc.. View insider buying and selling activity for Orchard Therapeutics.

Which major investors are buying Orchard Therapeutics stock?

ORTX stock was bought by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Vivo Capital LLC, Janus Henderson Group PLC, ArrowMark Colorado Holdings LLC, Casdin Capital LLC, State Street Corp, Two Sigma Investments LP, and Two Sigma Advisers LP. View insider buying and selling activity for Orchard Therapeutics.

How do I buy shares of Orchard Therapeutics?

Shares of ORTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Orchard Therapeutics' stock price today?

One share of ORTX stock can currently be purchased for approximately $9.34.

How big of a company is Orchard Therapeutics?

Orchard Therapeutics has a market capitalization of $908.41 million and generates $2.51 million in revenue each year. The company earns $-163,420,000.00 in net income (profit) each year or ($1.75) on an earnings per share basis. Orchard Therapeutics employs 180 workers across the globe.

What is Orchard Therapeutics' official website?

The official website for Orchard Therapeutics is www.orchard-tx.com.

How can I contact Orchard Therapeutics?

Orchard Therapeutics' mailing address is 108 CANNON STREET, LONDON X0, EC4N 6EU. The company can be reached via phone at 011-44-0-203-3846700.

This page was last updated on 6/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.